If you have bought ORPH you currently have a REAL opportunity to bag over the next 6-12 months. No hype just a damned good business / group of businesses that are both growing rapidly and will be profitable from Q3 Fillyerboots
Value is already there, the split has already been communicated. Stem will also need to raise as part of the listing. Value will also reduce within TILS exc Stem
RE: Goldman Sachs values Imutex at $1bn as at last year28 Jun 2020 21:01
Think when the general masses start to understand what we have, interest will grow and we re rate big time. Not to mention the progress and move to profitability of our core business in Q3 Dont want to be to bullish but I see an SP North of 50p over the next 6 months..Oh well I have said it now
may be more profitable as we can role all non core assets under 1 umbrella. Would also make the NEW company more interesting with a number of vaccines / technologies. If Prep bio also land a tie up with a Chinese pharma, as is hoped, things could get really tasty
You either trust the management team or not. Ask yourself these simple questions 1. Would Stroll and co have got involved if they did not think they could turn things around? 2.Does Stroll have a large amount of skin in the game? 2. Do you think the strategy is correct and likely to succeed ? 3. Are the new leadership team shrewd business people with exceptional track records? I answered these questions and took another big chunk......:-)